GLP-1 receptor agonist 24
GLP-1 receptor agonist 24 is a glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1 receptor agonist 24 activates the GLP-1R signaling pathway and regulates glucose metabolism-related responses, including glucose-stimulated insulin secretion and metabolic homeostasis. GLP-1 receptor agonist 24 can be used in studies of metabolism-related diseases.
For research use only. We do not sell to patients.
- CAS No.: 3103096-62-1
- Formula: C49H46F2N10O5
- Molecular Weight:892.95
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
GLP-1 10 μM (EC50) |
In Vitro
GLP-1 receptor agonist 24 (compound 520) exhibits an EC50 of 10 μM for cAMP accumulation, as measured by the HTRF assay in HEK293 cells stably expressing human GLP-1R[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 3103096-62-1
-
Molecular Weight 892.95
-
Formula C49H46F2N10O5
-
SMILES
C[C@H]1[C@@](N2C(C(N3[C@@]4([H])C5=C(N6C(N(C7=CC=C(N(N=C8)C)C8=C7F)C=C6)=O)N(C9=CC(C)=C(C(C)=C9)F)N=C5C[C@]3([H])CC4)=O)=CC%10=CC([C@@H]%11CC%12(OCC%11)CC%12)=CC=C%102)(C%13=NOC(N%13)=O)C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Human Islet Cell Culture
The method of preserving islets in vitro, with purified reduced immunogenicity. The steps are islet isolation, islet cell purification, in vitro determination of islet function and islet cell culture.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GLP-1 receptor agonist 24 Related Classifications
HY-188096 Related Classifications
Powered by Bioz